Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Accounts Payables: 2019-2024

Historic Accounts Payables for Legend Biotech (LEGN) over the last 2 years, with Dec 2024 value amounting to $38.6 million.

  • Legend Biotech's Accounts Payables rose 25.90% to $38.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $38.6 million, marking a year-over-year increase of 25.90%. This contributed to the annual value of $38.6 million for FY2024, which is 25.90% up from last year.
  • Legend Biotech's Accounts Payables amounted to $38.6 million in Q4 2024, which was up 25.90% from $30.7 million recorded in Q4 2023.
  • In the past 5 years, Legend Biotech's Accounts Payables registered a high of $38.6 million during Q4 2024, and its lowest value of $6,976 during Q2 2020.
  • Its 3-year average for Accounts Payables is $28.0 million, with a median of $31.8 million in 2022.
  • Per our database at Business Quant, Legend Biotech's Accounts Payables tumbled by 48.77% in 2020 and then skyrocketed by 157,597.82% in 2021.
  • Over the past 5 years, Legend Biotech's Accounts Payables (Quarterly) stood at $4.9 million in 2020, then surged by 43.41% to $7.0 million in 2021, then soared by 367.03% to $32.9 million in 2022, then decreased by 6.80% to $30.7 million in 2023, then climbed by 25.90% to $38.6 million in 2024.
  • Its Accounts Payables was $38.6 million in Q4 2024, compared to $30.7 million in Q4 2023 and $32.9 million in Q4 2022.